COMFORT
A. AGYEMANG |
Florida
Agricultural and Mechanical University College of Pharmacy and
Pharmaceutical Sciences |
| Major
|
Medicinal/Pharmaceutical
Chemistry |
| GPA: |
3.9/4.0 |
| Graduation
Date: |
August 2010 |
| Focus
of Research: |
To use the
natural product cryptolepine as a lead scaffold to develop new
agents as alternatives to Amphotericin B by introducing additional
substituents into the ring system. This research strategy will
enable me to investigate the possibility of increasing potency
and decreasing cytotoxicity as compared to Amphotericin B, the
current gold standard in antifungal drug development. Opportunistic
infections, including fungus infections, are caused by pathogens
that take advantage of a suppressed immune system. Conditions
such as HIV AIDS disease, organ transplantation, and long-term
use of corticosteroids, for example, cause either immune suppression
or some disruption in the immune system. With an estimate of over
40 million people living with AIDS around the globe and the increasing
development of resistance to current therapies, there is a continuing
need for new, more effective, anti-infective agents against opportunistic
infections. |
| Title
of Dissertation: |
“Development
of New Agents Against AIDS-Related Opportunistic Pathogens" |
| Degrees
Received: |
B.S., Chemistry,
University of Cape Coast (Ghana), June 2003 |
| Honors
Received: |
2007 Alpha
Kappa Mu Honors Society; 2005, Graduate Assistant in Areas of
National Need |
| AFPE
Award: |
Josiah Macy,
Jr. Foundation - AFPE Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
|
DANIEL
C. LANE |
University
of Michigan College of Pharmacy |
| Major
|
Social
& Administrative Sciences |
| GPA: |
3.62/4.30 |
| Graduation
Date: |
August 2009 |
| Focus
of Research: |
To study
the behavioral, biological, economic, and social influences effecting
individual and group health related decision making, with a focus
on the roles of emotion and motivation, and a particular interest
in
populations with mental disorders. The research will employ a
variety of mixed-methodological approaches
from a constructivist and participatory perspective. Interest
in decision-science is increasing within the pharmaceutical sciences
as the emphasis on translational research expands and the need
to move innovation from bench to bedside relies on patient health
related decision making. |
| Title
of Dissertation: |
“Investigating
the Role of Emotional Appraisals, Motives, and Values in Medication
Related Decision Processes” |
| Degrees
Received: |
Pharm. D.,
Pharmacy, Hampton University, May 2002 |
| Honors
Received: |
2008, AACP/Wal-Mart
Annual Conference Scholarship; 2008-2005, Horace H. Rackham Merit
Fellowship; 2005, Who's Who of Empowering Professionals, Omnicare
NWO Wonderful Individual Performance; 2003, CHRISTUS Jasper Memorial
Hospital Patient Care Director of the Year & Team of the Year;
2002, Dean’s List; 2001, AstraZeneca Professional Scholarship;
2001, Dean’s List; 2000, Eckerd Scholarship Recipient, Perrigo
Scholarship Recipient; 1999, Dean’s List; 1998-1996, Penfield
Scholar; 1997-1996, Dean's List |
| AFPE
Award: |
Josiah Macy,
Jr. Foundation - AFPE Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
MARIBEL REYES |
| University
of California at San Francisco School of Pharmacy |
| Major
|
Pharmacokinetics/Metabolism |
| GPA:
|
3.4/4.0 |
| Graduation
Date: |
September
2010 |
| Focus
of Research: |
To investigate
the effects of uremic toxins present in patients with chronic
kidney disease on hepatic transporters and on metabolizing enzymes
and, more specifically, to investigate the effects of uremic toxins
on the pharmacokinetics of non-renally excreted Class I, II, &
III drugs in cellular systems, in isolated perfused rat livers,
and finally in vivo in healthy volunteers and patients with chronic
kidney disease (DKD). It is hypothesized that the inhibition of
hepatica transporters and/or metabolizing enzymes by uremic toxins
may account for the observed decreases in the clearance and pharmacokinetics
of different classes of drugs taken by patients with renal failure.
This research can, ultimately, be useful in the dosing regimen
of non-renally cleared drugs in patients with chronic renal failure. |
| Title
of Dissertation: |
“Effects
of Uremic Toxin on Hepatic Transporters and Metabolism: Changes
in Pharmacokinetics of Class I, II, and III Drugs" |
| Degrees
Received: |
B.S., Pharmacology,
University of California, Santa Barbara, June 2002 |
| Honors
Received: |
2004-2003,
Fulbright Fellowship: 2002-1998, UCSB Chancellor’s Scholarship;
2001, NIH-Fogarty Minority International Research Training Program
Fellowship; 1999, Hispanic Scholarship Fund. |
| AFPE
Award: |
The Roche
Foundation - AFPE Pre-Doctoral Fellowship in the Pharmaceutical
Sciences |
